Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.97B | $19.80B | $19.29B | $17.60B | $15.56B | $12.73B | $13.53B | $11.44B |
| Cost of revenue | $3.27B | $3.58B | $3.37B | $3.01B | $2.45B | $2.23B | $2.40B | $2.17B |
| Gross profit | $19.71B | $16.22B | $15.92B | $14.59B | $13.11B | $10.50B | $11.13B | $9.27B |
| Gross margin | 85.8% | 81.9% | 82.5% | 82.9% | 84.3% | 82.5% | 82.2% | 81.0% |
| Research and development | $3.82B | $3.51B | $3.80B | $3.47B | $3.34B | $2.73B | $3.02B | $2.73B |
| Selling, general and administrative | $3.43B | $2.93B | $3.13B | $2.74B | $2.75B | $2.47B | $2.42B | $2.10B |
| Operating expenses | $10.73B | $7.31B | $7.55B | $7.23B | $6.24B | $6.81B | $5.98B | $7.74B |
| Operating income | $8.98B | $8.92B | $8.37B | $7.37B | $6.87B | $3.70B | $5.15B | $1.53B |
| Operating margin | 39.1% | 45.0% | 43.4% | 41.8% | 44.1% | 29.0% | 38.0% | 13.3% |
| EBITDA | $12.99B | $10.29B | $9.57B | $8.86B | $7.50B | $5.77B | $6.17B | $4.90B |
| Interest expense | $345.00M | $0 | $0 | — | $249.00M | $0 | $0 | — |
| Income before taxes | $9.25B | $8.85B | $8.27B | $7.23B | $6.78B | $3.46B | $5.04B | $1.59B |
| Income taxes | $2.15B | $1.45B | $1.63B | $1.65B | $1.12B | $697.00M | $628.50M | $618.10M |
| Net income | $7.10B | $7.40B | $6.64B | $5.58B | $5.66B | $2.76B | $4.41B | $970.30M |
| Net margin | 30.9% | 37.4% | 34.4% | 31.7% | 36.4% | 21.7% | 32.6% | 8.5% |
| EPS, basic | $7.95 | $8.27 | $7.41 | $6.22 | $6.30 | $3.07 | $4.90 | $1.08 |
| EPS, diluted | $7.94 | $8.26 | $7.39 | $6.21 | $6.29 | $3.06 | $4.88 | $1.07 |
| Diluted shares | 893.70M | 895.90M | 898.00M | 898.80M | 899.80M | 900.60M | 903.40M | 905.00M |
Figures describe Eli Lilly shares, not any token. As of Aug 5, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.
